BioStream

What BioStream does

BioStream is an early-stage health technology company developing a non-invasive, AI-powered urine-based diagnostic platform for continuous at-home monitoring of neurological conditions. The company's core product combines proprietary nano-sensor lateral flow immunoassay (LFA) strips — designed to detect brain-derived biomarkers in urine — with a smartphone application that applies computer vision and AI to interpret test strip patterns and transmit results to a secure clinician dashboard. The platform is positioned for two primary indications: pediatric hydrocephalus (where 50% of CSF shunts fail within two years, creating a need for daily shunt monitoring between hospital visits) and Normal Pressure Hydrocephalus (NPH) in elderly patients currently misdiagnosed with dementia, a population the company cites at 1.9 million.

The underlying technology architecture flows from at-home urine sample to LFA strip, to smartphone camera scan, to AI interpretation in the cloud, and finally to clinician-side decision support. Target users span three personas: pediatric patients with CSF shunts and their caregivers, seniors with dementia symptoms potentially attributable to treatable NPH, and the neurologists and neurosurgeons managing these patient cohorts. BioStream's go-to-market combines a direct-to-consumer route (kits and app for home use) with a clinical partnership route, where pilot studies are recruited via a dedicated partnerships email channel to establish clinical validation.

Commercially, BioStream has not publicly disclosed pricing; the implied business model involves hardware sales of LFA test strips to consumers plus a potential subscription or service component for clinician dashboard access. The company is privately held, founder-led by CEO Dr. Meital Bar and CBO Eng. Alex Dehtar, with a six-member core team that includes a Medical Director, an R&D Scientist, and two external advisors in medical device regulation and clinical research. BioStream lists institutional support from the Mehoudar Center for Inventors, UniMed, and JNF, and has secured public endorsements from senior neurosurgeons and patient advocacy leaders in the hydrocephalus community. At time of analysis, the company is in pilot recruitment phase with no disclosed funding rounds, revenue, or regulatory milestones.

Name

BioStream

Legal name

BioStream B

Website

https://biostream.health

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

BioStream is an early-stage health technology company developing AI-powered, non-invasive urine-based diagnostic systems for at-home neurological monitoring, targeting pediatric hydrocephalus patients and elderly patients with potentially treatable Normal Pressure Hydrocephalus.

Ownership category

akta.pro rank

Product category

Neurological Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category) (HLAHAOAH)

akta.pro secondary industries

Urinalysis & Routine Screening Diagnostics (HLAHAAAG), Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)

Keywords

• Non-invasive diagnostics
• Urine biomarker testing
• Neurological monitoring
• Lateral flow immunoassay
• AI medical diagnostics

Headquarters

HQ city

Colorado Springs

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. At-home diagnostic testing kits: BioStream generates revenue through sale of its lateral flow assay (LFA) test strips for home use, combined with the companion smartphone app. The model combines hardware (strips) with software (AI analysis and dashboard access).
2. SaaS/clinic dashboard subscriptions: Clinician dashboard provides real-time patient monitoring data, suggesting a subscription or service fee component for healthcare providers.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

BioStream develops and sells an AI-powered, non-invasive urine diagnostic system for neurological conditions. The product combines nanotechnology-based lateral flow immunoassay (LFA) strips that detect brain-derived biomarkers with smartphone-based AI image analysis and a secure clinician dashboard. It is sold as a daily two-minute at-home test kit for patients and families, with results transmitted to clinicians for continuous monitoring of hydrocephalus shunt function and Normal Pressure Hydrocephalus (NPH).

Product overview

BioStream offers a unified non-invasive diagnostic platform combining lateral flow immunoassay (LFA) test strips with AI-powered analysis. The core BioStream Diagnostic System uses a daily two-minute urine test to detect brain-derived biomarkers, which are scanned via smartphone and analyzed using AI before being securely transmitted to the Clinician Dashboard. The BioStream User App provides patients and families with easy-to-understand results and engagement features. The platform supports monitoring for hydrocephalus (shunt function) and Normal Pressure Hydrocephalus (NPH) misdiagnosis, targeting both pediatric and senior patient populations.

Differentiator

Problem solved

Functional benefit

Products and services

• BioStream Diagnostic System Non-invasive, AI-powered at-home urine diagnostic system that detects brain-derived biomarkers using lateral flow immunoassay (LFA) strips, smartphone scanning, and secure transmission to a clinician dashboard. Used by patients and families for continuous daily monitoring of neurological conditions, including CSF shunt function and Normal Pressure Hydrocephalus (NPH) triage, with clinical oversight via the integrated dashboard.

Quantifiable outcome

• 50% of CSF shunts fail within two years — BioStream enables early detection before symptoms appear
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Olink Holding: Proteomics company providing high-throughput biomarker detection platforms widely used in neurology and inflammation research. Comparable as a biomarker-focused company with AI/data components serving neurological drug development and diagnostics customers.
• Minomic International: Australian diagnostics company developing non-invasive urine-based tests (e.g., MiCheck for prostate cancer detection). Closely comparable to BioStream's core thesis of using urine biomarkers for non-invasive disease detection via immunoassay-based platforms.
• Quanterix: Ultra-sensitive biomarker detection company (Simoa platform) with neurology focus including Nf-L for neurodegeneration. Comparable as a biomarker detection technology company targeting neurological conditions, though Quanterix operates in lab-based settings rather than at-home LFA.
• Inflammatix: Diagnostics company developing host-response biomarker tests (HostDx) using immunoassay platforms to enable rapid clinical decision-making. Comparable as a biomarker-driven diagnostics startup pursuing non-invasive, rapid testing with AI-enabled interpretation.
• Cleveland Diagnostics: Diagnostics company developing non-invasive, biomarker-based tests using proprietary technology (e.g., IsoPSA for prostate cancer) with a focus on replacing invasive procedures. Directly comparable to BioStream's mission of non-invasive biomarker testing aimed at replacing invasive diagnostics.

Broad incumbents

• Bio-Rad Laboratories: Major life science tools and clinical diagnostics company with immunoassay and LFA capabilities. Comparable because it provides biomarker detection reagents and could easily extend into neurological urine biomarker assays, directly overlapping with BioStream's technical approach.
• Roche Diagnostics: World's largest IVD manufacturer with extensive immunoassay and lateral flow capabilities (e.g., SARS-CoV-2 Rapid Antigen Test) and integrated digital platforms. Comparable as the most likely strategic acquirer or competitor given its neurology franchise and global LFA distribution.
• Siemens Healthineers: Global IVD powerhouse offering immunoassay, clinical chemistry, and point-of-care platforms used by hospitals and reference labs worldwide. Comparable as a deep-pocketed incumbent that could pursue neurological urine biomarker assays and dominate reimbursement and clinical workflow integration.
• QuidelOrtho: Specialized rapid diagnostics and immunoassay company (QuickVue, Sofia LFA platforms). Comparable because it dominates point-of-care and at-home lateral flow markets with established FDA-cleared products and pharmacy distribution that BioStream's LFA strips would need to compete with.
• Abbott Diagnostics: Global IVD leader with deep lateral flow assay manufacturing (Binax, Panbio) and rapid diagnostic distribution into hospitals, pharmacies, and consumer channels. Comparable as a large-scale LFA producer that BioStream would compete against for shelf space, clinician adoption, and regulatory expertise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioStream